Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment

NCT00086632 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Stopped closed by sponser

Conditions

Ovarian Cancer

Interventions

DRUG: oregovomab

Sponsor

Unither Pharmaceuticals